Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-34

All these negative Nancie's with their knickers in a twist . Hate to break it to you all there is nothing at all negative from quarterly,
1) HIV trials in progress and expanding multiple locations.
2) Planning design of pivotal COVID trial. To do this properly and please potential partners / regulators doesn't happen overnight. Once a COVID plan in place with FDA guidance good luck buying any volume under 10cents. To me the absolute crucial step if using BIT225 is to design the trial properly (look what has happened to the likes of Mesoblast for not getting it right first time).